RLAY logo

RLAYRelay Therapeutics Inc

$14.24
$0.75
(5.56%)
Today
Closed $14.24
$0.09
(0.63%)
After Hours
Updated: 07:44 PM EDT
EarningsAug 6
Mkt Cap$2.94B
Vol2.09M
37

Bearish Sentiment

How do you feel about RLAY?

News
all
press releases
Is Relay Therapeutics a Buy After Promising Trial Results?
Key PointsRelay had its initial public offering in 2020...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms
Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN
24-7 Market News
News Placeholder
Why Relay Therapeutics Stock Popped on Wednesday
Key PointsThis was aided by a pair of bullish analyst updates...
Nasdaq News: Markets
News Placeholder
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib
Relay Therapeutics announced that it had commenced an offering of $175 million worth of shares of its common stock late Tuesday.
Stocktwits
News Placeholder
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders
Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.read more...
Benzinga
News Placeholder
RLAY Stock Lights Up On Vascular Anomalies Treatment Data Boost – 60% Of Patients Show Sharp Reduction In Lesion Volume
The trial evaluating Zovegalisib in vascular anomalies demonstrated the potential benefits of selectively targeting PI3Kα mutations.
Stocktwits
News Placeholder
142,228 Shares in Relay Therapeutics, Inc. $RLAY Bought by Sanctuary Advisors LLC
Sanctuary Advisors LLC bought a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 142,228 shares of the compan...
MarketBeat
News Placeholder
Relay Therapeutics (NASDAQ:RLAY) Releases Earnings Results, Misses Estimates By $0.06 EPS
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate...
MarketBeat
News Placeholder
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of -18.84% and -80.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Rating of "Moderate Buy" by Analysts
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven ratings firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.